MK-9470

MK-9470 is a radioligand and inverse agonist for the cannabinoid receptor type 1 (CB1). It was developed by Merck & Co. and has been used in its 11C (carbon-11) radiolabelled form to map the distribution of CB1 receptors in the brain, using positron emission tomography (PET).

Chemistry

MK-9470 is a selective inverse agonist for the CB1 receptor. Inverse agonists are agents that bind to the same receptor as an agonist but induce a pharmacological response opposite to that agonist.

Pharmacology

MK-9470 has been used in its radiolabelled form to map the distribution of CB1 receptors in the brain, using positron emission tomography (PET). This has allowed for the study of the role of CB1 receptors in various diseases and conditions, such as obesity, schizophrenia, and depression.

Clinical significance

The CB1 receptor is a promising target for the treatment of a variety of conditions, including obesity, addiction, and certain types of pain. Therefore, understanding the distribution and function of this receptor in the brain is of significant clinical interest.

See also

• Cannabinoid receptor
• Inverse agonist
• Positron emission tomography

References

MK-9470 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski